These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 36189355)
1. Biofilm formation is not an independent risk factor for mortality in patients with Chiang TT; Huang TW; Sun JR; Kuo SC; Cheng A; Liu CP; Liu YM; Yang YS; Chen TL; Lee YT; Wang YC Front Cell Infect Microbiol; 2022; 12():964539. PubMed ID: 36189355 [TBL] [Abstract][Full Text] [Related]
2. Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients. Jain M; Sharma A; Sen MK; Rani V; Gaind R; Suri JC Microb Pathog; 2019 Mar; 128():75-81. PubMed ID: 30562602 [TBL] [Abstract][Full Text] [Related]
3. Characterization of carbapenem-resistant hypervirulent Acinetobacter baumannii strains isolated from hospitalized patients in the mid-south region of China. Li J; Yu T; Luo Y; Peng JY; Li YJ; Tao XY; Hu YM; Wang HC; Zou MX BMC Microbiol; 2020 Sep; 20(1):281. PubMed ID: 32928115 [TBL] [Abstract][Full Text] [Related]
4. Carbapenem-resistant versus carbapenem-susceptible Acinetobacter baumannii bacteremia in a Greek intensive care unit: risk factors, clinical features and outcomes. Routsi C; Pratikaki M; Platsouka E; Sotiropoulou C; Nanas S; Markaki V; Vrettou C; Paniara O; Giamarellou H; Roussos C Infection; 2010 Jun; 38(3):173-80. PubMed ID: 20224962 [TBL] [Abstract][Full Text] [Related]
5. Multicenter Study of the Relationship between Carbapenem MIC Values and Clinical Outcome of Patients with Acinetobacter Bacteremia. Yang YS; Wang YC; Kuo SC; Chen CT; Liu CP; Liu YM; Chen TL; Lee YT Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652230 [TBL] [Abstract][Full Text] [Related]
6. Risk Factors for Mortality in Children with Choe YJ; Lee HJ; Choi EH Microb Drug Resist; 2019 Oct; 25(8):1210-1218. PubMed ID: 31120349 [No Abstract] [Full Text] [Related]
7. Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections. Esterly JS; Griffith M; Qi C; Malczynski M; Postelnick MJ; Scheetz MH Antimicrob Agents Chemother; 2011 Oct; 55(10):4844-9. PubMed ID: 21825287 [TBL] [Abstract][Full Text] [Related]
8. Risk factors for mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia: impact of appropriate antimicrobial therapy. Kim YJ; Kim SI; Hong KW; Kim YR; Park YJ; Kang MW J Korean Med Sci; 2012 May; 27(5):471-5. PubMed ID: 22563209 [TBL] [Abstract][Full Text] [Related]
9. Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia. Liu CP; Shih SC; Wang NY; Wu AY; Sun FJ; Chow SF; Chen TL; Yan TR J Microbiol Immunol Infect; 2016 Dec; 49(6):934-940. PubMed ID: 25553994 [TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics and outcomes of community and hospital-acquired Acinetobacter baumannii bacteremia. Chusri S; Chongsuvivatwong V; Silpapojakul K; Singkhamanan K; Hortiwakul T; Charernmak B; Doi Y J Microbiol Immunol Infect; 2019 Oct; 52(5):796-806. PubMed ID: 31031096 [TBL] [Abstract][Full Text] [Related]
11. Acinetobacter baumannii Biofilm Formation: Association with Antimicrobial Resistance and Prolonged Survival under Desiccation. Choudhary M; Shrivastava R; Vashistt J Curr Microbiol; 2022 Oct; 79(12):361. PubMed ID: 36253556 [TBL] [Abstract][Full Text] [Related]
12. [Risk factors and resistance patterns of invasive Ge YL; Shan QW; Qiu Y; Zhou SP; Cheng YB; Wang F; Yang JW; Wan CM; Zhu Y; Xu Y; Chen MX; Lin DJ; Zhu CH; Zeng M Zhonghua Er Ke Za Zhi; 2022 Aug; 60(8):762-768. PubMed ID: 35922185 [No Abstract] [Full Text] [Related]
13. Risk factors and clinical outcomes of patients with carbapenem-resistant Acinetobacter baumannii bacteremia. Huang ST; Chiang MC; Kuo SC; Lee YT; Chiang TH; Yang SP; Ti-Yin ; Chen TL; Fung CP J Microbiol Immunol Infect; 2012 Oct; 45(5):356-62. PubMed ID: 22575430 [TBL] [Abstract][Full Text] [Related]
14. Acinetobacter baumannii in Southern Croatia: clonal lineages, biofilm formation, and resistance patterns. Kaliterna V; Kaliterna M; Hrenović J; Barišić Z; Tonkić M; Goic-Barisic I Infect Dis (Lond); 2015; 47(12):902-7. PubMed ID: 26365683 [TBL] [Abstract][Full Text] [Related]
15. Risk factors and clinical outcomes of multidrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Thailand. Anunnatsiri S; Tonsawan P Southeast Asian J Trop Med Public Health; 2011 May; 42(3):693-703. PubMed ID: 21706949 [TBL] [Abstract][Full Text] [Related]
16. Adaptations of carbapenem resistant Sharma S; Das A; Banerjee T; Barman H; Yadav G; Kumar A J Med Microbiol; 2021 Mar; 70(3):. PubMed ID: 33739918 [No Abstract] [Full Text] [Related]
17. Correlation of biofilm formation and antibiotic resistance among clinical and soil isolates of Acinetobacter baumannii in Iraq. Hassan PA; Khider AK Acta Microbiol Immunol Hung; 2020 Oct; 67(3):161-170. PubMed ID: 31833386 [TBL] [Abstract][Full Text] [Related]
18. Biofilm formation is not associated with worse outcome in Acinetobacter baumannii bacteraemic pneumonia. Wang YC; Huang TW; Yang YS; Kuo SC; Chen CT; Liu CP; Liu YM; Chen TL; Chang FY; Wu SH; How CK; Lee YT Sci Rep; 2018 May; 8(1):7289. PubMed ID: 29740176 [TBL] [Abstract][Full Text] [Related]
19. Multicenter Study of Clinical Features of Breakthrough Acinetobacter Bacteremia during Carbapenem Therapy. Lee YT; Wang YC; Kuo SC; Chen CT; Liu CP; Liu YM; Chen TL; Yang YS Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674056 [TBL] [Abstract][Full Text] [Related]
20. Risk and Prognostic Factors for Multidrug-Resistant Acinetobacter Baumannii Complex Bacteremia: A Retrospective Study in a Tertiary Hospital of West China. Liu Q; Li W; Du X; Li W; Zhong T; Tang Y; Feng Y; Tao C; Xie Y PLoS One; 2015; 10(6):e0130701. PubMed ID: 26083415 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]